A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

ClinicalTrials.gov ID: NCT06016088

Public ClinicalTrials.gov record NCT06016088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

Study identification

NCT ID: NCT06016088
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Respirion Pharmaceuticals Pty Ltd; Industry
Enrollment: 71 participants

Conditions and interventions

Conditions

Interventions

RSP-1502 Drug
Tobramycin inhalation solution Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2024
Primary completion: Apr 14, 2026
Completion: Jun 21, 2026
Last update posted: Jun 24, 2026

2024 – 2026

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Tucson Cystic Fibrosis Center	Tucson	Arizona	85750	—
Center for Cystic Fibrosis at Keck Medical Center of USC	Los Angeles	California	90033	—
Stanford University Medical Center	Palo Alto	California	94305	—
Augusta University	Augusta	Georgia	30912	—
The Cystic Fibrosis Institute	Northfield	Illinois	60093	—
Tulane University	New Orleans	Louisiana	70118	—
The Minnesota Cystic Fibrosis Center	Minneapolis	Minnesota	55403	—
Washington University School of Medicine	St Louis	Missouri	63130	—
Columbia University Cystic Fibrosis Program	New York	New York	10027	—
Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	—
Nationwide Children's Hospital	Columbus	Ohio	43205	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Dell Children's Medical Center of Central Texas	Austin	Texas	78723	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06016088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 24, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06016088 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →